Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02712138
Other study ID # BGI 06-2018
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 20, 2018
Est. completion date February 28, 2021

Study information

Verified date February 2023
Source CENTOGENE GmbH Rostock
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Gilbert disease from blood


Description:

Gilbert syndrome is a mild genetic liver disorder in which the body cannot properly process bilirubin, a yellowish waste product that is formed when old or worn out red blood cells are broken down (hemolysis). It is inherited as an autosomal recessive trait. Individuals with Gilbert syndrome have elevated levels of bilirubin (hyperbilirubinemia), because they have a reduced level of a specific liver enzyme required for elimination of bilirubin. Most affected individuals have no symptoms or may only exhibit mild yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Jaundice may not be apparent until adolescence. Bilirubin levels may increase following stress, exertion, dehydration, alcohol consumption, fasting, and/or infection. In some individuals, jaundice may only be apparent when triggered by one of these conditions. Some affected individuals have reported vague, unspecific symptoms including fatigue, weakness and gastrointestinal symptoms such as nausea, abdominal discomfort, and diarrhea. Gilbert syndrome is diagnosed more often in males than females. The disorder affects approximately 3-7 percent of individuals in the general population, and affects individuals of all races. It is present at birth, but may remain undiagnosed until the late teens or early twenties. Gilbert syndrome is caused by mutations to the UGT1A1 gene located on the long arm (q) of chromosome 2 (2q37). The UGT1A1 gene contains instructions for creating (encoding) a liver enzyme known as uridine disphosphate-glucuronosyltransferase-1A1 (UGT1A1). This enzyme is required for the conversion (conjugation) and subsequent excretion of bilirubin from the body. Individuals with Gilbert syndrome retain approximately one third of the normal UGT1A1 enzyme activity and are able to conjugate enough bilirubin to prevent symptoms from developing. Mild jaundice associated with Gilbert syndrome occurs due to reduced amounts of this enzyme, which results in the accumulation of unconjugated bilirubin in the body. Bilirubin circulates in the liquid portion of the blood (plasma) bound to a protein called albumin; this is called unconjugated bilirubin, which does not dissolve in water (water-insoluble). Normally, this unconjugated bilirubin is taken up by the liver cells and, with the help of the UGT1A1 enzyme, is converted to form water-soluble bilirubin glucuronides (conjugated bilirubin), which are then excreted in the bile. The bile is stored in the gall bladder and, when called upon, passes into the common bile duct and then into the upper portion of the small intestine (duodenum) and aids in digestion. Most bilirubin is eliminated from the body in the feces. New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood (plasma) of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to identify and validate a new biochemical marker from the plasma of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 28, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Months and older
Eligibility INCLUSION CRITERIA - Informed consent will be obtained from the patient or the parents before any study related procedures. - Patients of both genders older than 2 months - The patient has a diagnosis of Gilbert disease or a high-grade suspicion for Gilbert disease - High-grade suspicion present, if one or more inclusion criteria are valid: 1. - Positive family anamnesis for Gilbert disease 2. - Hyperbilirubinemia 3. - Abdominal pain 4. - Irritable bowel syndrome 5. - Familial nonhemolytic jaundice EXCLUSION CRITERIA - No Informed consent from the patient or the parents before any study related procedures. - Patients of both gender younger than 2 months - No diagnosis of Gilbert disease or no valid criteria for profound suspicion of Gilbert disease

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Children Hospital, Faculty of Medicine, Cairo University Cairo
India Amrita Institute of Medical Sciences & Research Centre Cochin Kerala
India Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN) Mumbai
Sri Lanka Lady Ridgeway Hospital for Children Colombo 8

Sponsors (1)

Lead Sponsor Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Egypt,  India,  Sri Lanka, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sequencing of the Gilbert disease related gene Next-Generation Sequencing (NGS) of the UGT1A1 gene will be performed. The mutation will be confirmed by Sanger sequencing. 4 weeks
Secondary The Gilbert disease specific biomarker candidates finding The quantitative determination of small molecules (molecular weight 150-700 kD, given as ng/µl) within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry (LC/MRM-MS) and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker. 24 months
See also
  Status Clinical Trial Phase
Completed NCT00383318 - Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Completed NCT00115544 - Safety and Pharmacology of Stanate Phase 2
Completed NCT01622699 - Implementation of a Transcutaneous Bilirubinometer N/A
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Completed NCT00288600 - Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease Phase 4
Completed NCT02774434 - Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age N/A
Completed NCT01550627 - Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy Phase 0
Completed NCT00653874 - Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates Phase 3
Recruiting NCT03564678 - Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT04897113 - Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old N/A
Recruiting NCT01944696 - Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants? N/A
Completed NCT00635375 - Comparative Study of Phototherapy for Hyperbilirubinemia N/A
Completed NCT03195998 - Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants
Terminated NCT02685189 - Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)
Completed NCT02446951 - Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department
Terminated NCT01136577 - Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn N/A
Completed NCT04271098 - The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries
Completed NCT02691156 - Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
Completed NCT00004381 - Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia Phase 2